Soligenix Inc. (NASDAQ:SNGX) Sees Large Decline in Short Interest

Posted by Francis Steltz on Aug 28th, 2026

Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the target of a significant drop in short interest in August. As of August 14th, there was short interest totaling 207,637 shares, a drop of 64.5% from the July 30th total of 585,019 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 171,039 shares, the short-interest ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Soligenix has an average rating of “Sell”.

Get Our Latest Analysis on SNGX

Soligenix Price Performance

Shares of SNGX stock traded down $0.00 during trading hours on Friday, reaching $0.38. The company had a trading volume of 139,469 shares, compared to its average volume of 2,996,985. The company has a 50 day moving average of $0.38 and a 200 day moving average of $0.72. The firm has a market cap of $5.59 million, a price-to-earnings ratio of -0.38 and a beta of 1.93. Soligenix has a 1-year low of $0.28 and a 1-year high of $3.22.

Soligenix (NASDAQ:SNGX – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. As a group, sell-side analysts forecast that Soligenix will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Soligenix

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new stake in shares of Soligenix in the 3rd quarter valued at about $821,000. Two Sigma Investments LP bought a new position in Soligenix during the 3rd quarter worth approximately $102,000. Virtu Financial LLC bought a new position in Soligenix during the 3rd quarter worth approximately $59,000. Banco BTG Pactual S.A. acquired a new position in Soligenix during the third quarter valued at approximately $54,000. Finally, Jane Street Group LLC acquired a new position in Soligenix during the fourth quarter valued at approximately $51,000. 3.60% of the stock is currently owned by institutional investors and hedge funds.

About Soligenix

(Get Free Report)

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.